APPLIED DNA SCIENCES INC (APDN)
US03815U4094 - Common Stock
We assign a fundamental rating of 3 out of 10 to APDN. APDN was compared to 55 industry peers in the Life Sciences Tools & Services industry. While APDN seems to be doing ok healthwise, there are quite some concerns on its profitability. APDN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
APDN had negative earnings in the past year.
APDN had a negative operating cash flow in the past year.
In the past 5 years APDN always reported negative net income.
APDN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -45.06%, APDN is not doing good in the industry: 89.09% of the companies in the same industry are doing better.
APDN has a worse Return On Equity (-60.69%) than 74.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.06% | ||
| ROE | -60.69% | ||
| ROIC | N/A |
ROA(3y)-69.86%
ROA(5y)-115.01%
ROE(3y)-131.44%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APDN has a Gross Margin of 25.04%. This is in the lower half of the industry: APDN underperforms 78.18% of its industry peers.
APDN's Gross Margin has declined in the last couple of years.
APDN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 25.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.92%
GM growth 5Y-9.74%
2. Health
2.1 Basic Checks
APDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APDN has been increased compared to 1 year ago.
Compared to 5 years ago, APDN has more shares outstanding
There is no outstanding debt for APDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
APDN has an Altman-Z score of -26.70. This is a bad value and indicates that APDN is not financially healthy and even has some risk of bankruptcy.
APDN has a worse Altman-Z score (-26.70) than 94.55% of its industry peers.
APDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -26.7 |
ROIC/WACCN/A
WACC11.28%
2.3 Liquidity
APDN has a Current Ratio of 3.91. This indicates that APDN is financially healthy and has no problem in meeting its short term obligations.
APDN's Current ratio of 3.91 is fine compared to the rest of the industry. APDN outperforms 65.45% of its industry peers.
APDN has a Quick Ratio of 3.76. This indicates that APDN is financially healthy and has no problem in meeting its short term obligations.
APDN has a Quick ratio of 3.76. This is in the better half of the industry: APDN outperforms 67.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.76 |
3. Growth
3.1 Past
The earnings per share for APDN have decreased strongly by -18.40% in the last year.
Looking at the last year, APDN shows a very negative growth in Revenue. The Revenue has decreased by -78.96% in the last year.
The Revenue has been growing by 27.92% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-18.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%109.79%
Revenue 1Y (TTM)-78.96%
Revenue growth 3Y90.55%
Revenue growth 5Y27.92%
Sales Q2Q%-72.68%
3.2 Future
The Earnings Per Share is expected to grow by 38.89% on average over the next years. This is a very strong growth
APDN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -39.60% yearly.
EPS Next Y52.94%
EPS Next 2Y38.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-75.35%
Revenue Next 2Y-39.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
APDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APDN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as APDN's earnings are expected to grow with 38.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.89%
EPS Next 3YN/A
5. Dividend
5.1 Amount
APDN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
APPLIED DNA SCIENCES INC
NASDAQ:APDN (11/22/2024, 5:56:51 PM)
After market: 0.1599 +0 (+3.16%)0.155
0 (-2.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.82M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.06% | ||
| ROE | -60.69% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 25.04% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.76 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-18.4%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y52.94%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-78.96%
Revenue growth 3Y90.55%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y